Welcome to our dedicated page for Lyra Therapeutics news (Ticker: LYRA), a resource for investors and traders seeking the latest updates and insights on Lyra Therapeutics stock.
Lyra Therapeutics, Inc. (LYRA) is a clinical-stage biotechnology company pioneering targeted therapies for chronic ear, nose, and throat conditions. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's innovative drug-delivery platforms and clinical progress.
Access timely reports on LYRA's XTREO technology advancements, regulatory milestones, and research collaborations. Our curated collection features press releases covering clinical trial outcomes, product development updates, and strategic partnerships in the ENT therapeutics space.
Key content includes analyses of the company's bioresorbable matrix systems, progress in chronic rhinosinusitis treatment development, and financial performance updates. Bookmark this page for streamlined tracking of LYRA's mission to transform localized drug delivery in otolaryngology.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) has resumed screening and enrollment in its ENLIGHTEN II clinical trial for LYR-210, a bioresorbable nasal implant aimed at treating chronic rhinosinusitis (CRS). The trial targets patients who have not responded to medical management. Resumption of enrollment follows a temporary pause for in-house manufacturing adjustments, which Lyra anticipates will strengthen regulatory compliance. The company is also on track with the first ENLIGHTEN trial, with pivotal results expected in the first half of 2024. Each trial will enroll 180 patients, supporting a New Drug Application to the FDA for LYR-210. The product is designed to provide up to six months of sustained anti-inflammatory treatment, showing promising Phase 2 results with no serious adverse events reported.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported its financial results for Q4 and full year 2022, highlighting significant advancements in its clinical trials and production capabilities. The company initiated two Phase 3 trials for LYR-210 aimed at chronic rhinosinusitis (CRS), with completion of enrollment expected by mid-2023. Additionally, data from the Phase 2 BEACON trial for LYR-220 is expected in Q4 2023. The transition to in-house manufacturing is set to enhance product quality and supply. Financially, Lyra recorded a net loss of $55.3 million for 2022, with cash reserves projected to sustain operations through mid-2024.
FAQ
What is the current stock price of Lyra Therapeutics (LYRA)?
What is the market cap of Lyra Therapeutics (LYRA)?
